MTIP closed its second healthtech-focused growth fund above its target with $250 million of capital commitments this week.
The fund, MTIP Fund II, is one of the few healthtech-specific private equity funds focused on Europe and provides growth capital to entrepreneurial and fast-growing digital health and digitally connected medical device companies.
Investors in the new fund include pension funds, family offices, hospitals and foundations. The Swiss firm said that the fund has earned a ‘dark green’ fund under Article 9 of the EU’s Sustainable Finance Disclosure Regulation, which is for the fund’s objective to target sustainable investments.
MTIP, based in Basel, Switzerland, provides up to €25 million in funding to companies.
“We are excited to announce the successful closing of our second fund and continue our mission to build the healthtech leaders of tomorrow,” said Dr. Christoph Kausch, managing partner at MTIP. “The trust our investors have put in us is a great endorsement of our strategy that’s built on our singular focus and proven approach to value creation.”
While the pandemic has accelerated innovation in the healthcare sector and led to the of adoption new technologies, MTIP said its investment team sources the most significant players in various markets and closely observes relevant healthcare and societal trends.
“MTIP has a unique expertise in healthtech and fosters innovation in this under-served private equity sector,” said Dr. Andreas Schönenberger, CEO of Swiss health insurance company Sanitas, is one of the investors in MTIP Fund II. “Our collaboration with MTIP gives us access to innovative healthtech solutions that enable us to generate added value for our customers.”
So far, MTIP has made five investments out of its second fund: Oviva, Trialbee, Koa Health, Intelligencia and Mediktor.